Aimovig for Migraine prophylaxis
Quick answer: Aimovig is used for Migraine prophylaxis as part of a cgrp receptor antagonist monoclonal antibody treatment regimen. Erenumab is a human monoclonal antibody that binds the calcitonin gene-related peptide (CGRP) receptor, blocking its activity in migraine pathophysiology The specific dosing for Migraine prophylaxis is determined by your prescriber based on individual factors.
Why is Aimovig used for Migraine prophylaxis?
Aimovig belongs to the CGRP receptor antagonist monoclonal antibody class. Erenumab is a human monoclonal antibody that binds the calcitonin gene-related peptide (CGRP) receptor, blocking its activity in migraine pathophysiology This action makes it useful for treating or managing Migraine prophylaxis in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Aimovig is the right choice for a specific patient depends on the type and severity of Migraine prophylaxis, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for Migraine prophylaxis
Common adult dosing range: 70-140 mg subcutaneously once monthly. The actual dose for Migraine prophylaxis depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Aimovig medicine page.
What to expect
Aimovig treatment for Migraine prophylaxis typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on Migraine prophylaxis
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Aimovig is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all CGRP receptor antagonist monoclonal antibody for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Aimovig
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Aimovig full prescribing information · All CGRP receptor antagonist monoclonal antibody alternatives
Frequently asked questions
How effective is Aimovig for Migraine prophylaxis?
Effectiveness varies by individual response, dose, and severity. Aimovig is one of several treatment options for Migraine prophylaxis, supported by clinical evidence within the cgrp receptor antagonist monoclonal antibody class. Discuss expected response with your prescriber.
How long do I need to take Aimovig for Migraine prophylaxis?
Treatment duration depends on the nature of Migraine prophylaxis — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Aimovig when used for Migraine prophylaxis?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Aimovig for Migraine prophylaxis?
Yes. Multiple medicines and non-drug options exist for Migraine prophylaxis. Alternatives within the cgrp receptor antagonist monoclonal antibody class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.